Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Good
|
New words:
absence, Actonel, agonist, alliance, America, asterisk, Avodart, beta, cachexia, capacity, CKD, clarity, constitute, correct, corrected, counsel, cure, Dalton, deep, default, denied, description, documented, Effexor, elevation, entirety, ESRD, evidence, Evista, evolving, exhibit, FARESTON®net, foregoing, Fosamax, frequency, gynecomastia, healthcare, hepatic, hinder, hot, implement, IND, intent, interinstitutional, investor, kidney, legitimate, lengthy, letter, male, marked, marketplace, Megace, myocardial, myriad, nuclear, ocular, oncology, OstarineTM, OstarineTMand, OstarineTMdrug, OSU, owed, pharmacokinetic, pharmacological, preclude, prevail, professor, proscribed, pulmonary, purport, reacquired, recommended, reformulate, reproductive, residual, resolved, revised, salary, sarcopenia, substance, substantive, summer, thromboembolic, unblinded, unmet, unwilling, urology, vein, version, Vice, withdrawn, worsening, Zometa
Removed:
achieved, affiliate, agency, agent, andromustine, anticancer, APB, Biomed, burn, competitor, computer, currency, deposit, derivative, EaglePicher, exclusively, exercisable, exercised, fat, February, flow, forma, fracture, frail, furniture, gather, half, hypothetical, IIIb, individual, intrinsic, invested, IPO, liquid, maximizing, meeting, minimum, mitigate, modified, modulate, objective, occurred, offsetting, oral, original, ostarine, OSURF, portfolio, positive, preceding, preserve, pro, proceeding, promoting, prostarine, rata, recurrent, refractory, remaining, reserved, restated, reversed, skin, sufficiently, transition, unamortized, unvested, unwanted, upfront
Filing tables
Filing exhibits
Related press release
ONCT similar filings
Filing view
External links
Exhibit 10.28
COMPENSATION INFORMATION FOR EXECUTIVE OFFICERS
The table below provides information regarding the base salary of each executive officer of GTx, Inc.effective as of January 1, 2007:
Base | ||||||
Executive Officer | Title | Compensation | ||||
Mitchell S. Steiner, M.D., F.A.C.S. | Chief Executive Officer and Vice-Chairman of the Board of Directors | $ | 446,250 | |||
Marc S. Hanover | President and Chief Operating Officer | $ | 306,600 | |||
Henry P. Doggrell | Vice President, General Counsel and Secretary | $ | 265,650 | |||
Mark E. Mosteller | Vice President, Chief Financial Officer and Treasurer | $ | 246,750 | |||
James T. Dalton | Vice President, Preclinical Research & Development | $ | 252,000 | |||
K. Gary Barnette | Vice President, Clinical Research & Development Strategy | $ | 239,200 | |||
Gregory A. Deener | Vice President, Sales & Marketing, Product Commercialization | $ | 234,000 |
18